Venus Remedies Board Approves Q2 2026 Unaudited Results, MOA Alteration

Venus Remedies Limited's Board of Directors met on July 20, 2026, to approve the unaudited financial results (Consolidated and Standalone) for the quarter ended June 30, 2026, along with the auditor's limited review report. The board also approved revisions to the proposed alteration of the Memorandum of Association (MOA), primarily to align the object clause with the Companies Act, 2013, and update it with current and proposed business activities in the pharmaceutical sector. The revised MOA will be presented to shareholders for approval via a special resolution at the upcoming 37th Annual General Meeting. The trading window for designated persons was closed from July 1, 2026, until 48 hours after the financial results declaration.